A Comparison of Pollen and Syrup Exposure Routes in Bombus impatiens (Hymenoptera: Apidae) Microcolonies: Implications for Pesticide Risk Assessment.

Bumble bees are important pollinators for both native plants and managed agricultural systems. Accumulating evidence has shown that pesticides, including neonicotinoids, can have a range of adverse effects on bumble bee health. Most laboratory studies that assess the effects of chronic neonicotinoid exposure on bumble bees use syrup as the delivery vehicle, rather than pollen. However, in the field, it is likely that bumble bees are exposed to neonicotinoids in both nectar (syrup) and pollen. To examine the potential for different effects based on the vehicle, we compared two studies of chronic exposure to the neonicotinoid acetamiprid in Bombus impatiens microcolonies. We examined correlations between microcolony endpoints and identified associations between the timing of colony pollen and syrup consumption and drone production. Furthermore, in line with previous results, we found that average drone weight was affected at a range of doses only when microcolonies were exposed to acetamiprid via pollen. In general, our analyses point to the importance of the treatment vehicle and suggest that critical effects on developing brood could be missed when neonicotinoid exposure occurs only through syrup.

Effects of the Neonicotinoid Acetamiprid in Pollen on Bombus impatiens Microcolony Development.

Honey bees and other wild bee species including bumble bees have experienced population declines in recent decades. Although many stressors are implicated in bee population declines, much attention has focused on neonicotinoid pesticides, which are widely used and known to be toxic to pollinators. One neonicotinoid, acetamiprid, has been studied very little in bumble bees, despite its use on bumble bee-pollinated crops. We assessed the impacts of acetamiprid to the North American bumble bee Bombus impatiens using the microcolony model. We examined nest growth, development, and subsequent nest productivity as measured by drone production. We found that high concentrations of acetamiprid in pollen (4520 µg/kg) significantly impacted nest growth, development, and, ultimately, reproduction (drone production). We found the no-observable-adverse effect level to be 45.2 µg/kg. Overall, acetamiprid has the potential to negatively impact reproductive endpoints for B. impatiens. However, effects occurred at concentrations substantially higher than expected environmental concentrations that would be achieved when following label rates. Further work is required to assess the effects of this pesticide on B. impatiens via alternate routes of exposure and on queenright colonies. Environ Toxicol Chem 2020;39:2560-2569. © 2020 SETAC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

G protein betagamma subunits as targets for small molecule therapeutic development.

G proteins mediate the action of G protein coupled receptors (GPCRs), a major target of current pharmaceuticals and a major target of interest in future drug development. Most pharmaceutical interest has been in the development of selective GPCR agonists and antagonists that activate or inhibit specific GPCRs. Some recent thinking has focused on the idea that some pathologies are the result of the actions of an array of GPCRs suggesting that targeting single receptors may have limited efficacy. Thus, targeting pathways common to multiple GPCRs that control critical pathways involved in disease has potential therapeutic relevance. G protein betagamma subunits released from some GPCRs upon receptor activation regulate a variety of downstream pathways to control various aspects of mammalian physiology. There is evidence from cell- based and animal models that excess Gbetagamma signaling can be detrimental and blocking Gbetagamma signaling has salutary effects in a number of pathological models. Gbetagamma regulates downstream pathways through modulation of enzymes that produce cellular second messengers or through regulation of ion channels by direct protein-protein interactions. Thus, blocking Gbetagamma functions requires development of small molecule agents that disrupt Gbetagamma protein interactions with downstream partners. Here we discuss evidence that small molecule targeting Gbetagamma could be of therapeutic value. The concept of disruption of protein-protein interactions by targeting a "hot spot" on Gbetagamma is delineated and the biochemical and virtual screening strategies for identification of small molecules that selectively target Gbetagamma functions are outlined. Evaluation of the effectiveness of virtual screening indicates that computational screening enhanced identification of true Gbetagamma binding molecules. However, further refinement of the approach could significantly improve the yield of Gbetagamma binding molecules from this screen that could result in multiple candidate leads for future drug development.

Differential targeting of Gbetagamma-subunit signaling with small molecules.

G protein betagamma subunits have potential as a target for therapeutic treatment of a number of diseases. We performed virtual docking of a small-molecule library to a site on Gbetagamma subunits that mediates protein interactions. We hypothesized that differential targeting of this surface could allow for selective modulation of Gbetagamma subunit functions. Several compounds bound to Gbetagamma subunits with affinities from 0.1 to 60 muM and selectively modulated functional Gbetagamma-protein-protein interactions in vitro, chemotactic peptide signaling pathways in HL-60 leukocytes, and opioid receptor-dependent analgesia in vivo. These data demonstrate an approach for modulation of G protein-coupled receptor signaling that may represent an important therapeutic strategy.